SGO 2019 Archives - Page 2 of 3 - Cancer Therapy Advisor

Double mutants may predict resistance to PARP inhibitors and could also indicate sensitivity to alte

SGO 2019

Evaluating Chemotherapy Plus Adjuvant Radiation Therapy for Vulvar Cancer

By

March 18, 2019

Researchers found that adjuvant chemoradiation therapy was preferable over adjuvant radiation therapy alone for squamous cell carcinoma of the vulva.

Critics worry that changes to the FDA’s drug approval process could lead to increased off-label pres

SGO 2019

Maintenance Olaparib May Be More Cost-Effective Than Bevacizumab in BRCA-Mutant Ovarian Cancer

By

Susan Moench, PhD, PA-C

March 18, 2019

Researchers estimated cost effectiveness for first-line maintenance therapy with bevacizumab or olaparib in women with BRCA-mutant ovarian cancer.

The future of chemotherapy-based options for patients with HER2-negative MBC is evolving, with emerg

SGO 2019

Pembrolizumab, Bevacizumab, Cyclophosphamide Combination for Ovarian Cancer: Promising Phase II Results

By

Susan Moench, PhD, PA-C

March 17, 2019

Tumor response rates were higher in patients with platinum-sensitive recurrent ovarian cancers, according to researchers

The high cost of CAR-T therapy concerns patient advocates who worry about the "financial toxicity" i

SGO 2019

Social and Financial Assistance Programs to Overcome Barriers for Patients With Cervical Cancer

By

Susan Moench, PhD, PA-C

March 16, 2019

According to researchers, the prevalence of HPV-16 infection in a cohort of young women in Japan decreased from 1.3% in 2014 to 0% in 2017.

SGO 2019

HPV Vaccination Influences Prevalence of Type-Specific HPV Infection

By

Susan Moench, PhD, PA-C

March 16, 2019

According to researchers, the prevalence of HPV-16 infection in a cohort of young women in Japan decreased from 1.3% in 2014 to 0% in 2017.

Patients with cervical cancer who receive fosaprepitant in addition to palonosetron and dexamethason

SGO 2019

Racial Disparities in the Use of Brachytherapy to Treat Cervical Cancer

By

Susan Moench, PhD, PA-C

March 16, 2019

Black women with locally advanced cervical cancer are significantly less likely to receive brachytherapy compared with non-black women with this disease.

Managing adverse effects after starting a TKI can be challenging, and health care practitioners ofte

SGO 2019

The Relationship Between Niraparib Dose Reduction and Efficacy in Ovarian Cancer

By

Susan Moench, PhD, PA-C

March 16, 2019

In the QUADRA trial patients with low baseline platelet count or low body weight were more likely to experience grade 3/4 adverse events.

Gynecologic Cancer, SGO 2019

Experience for Women With Ovarian Cancer After Multiple Lines of PARP Inhibitor Therapy

By

Susan Moench, PhD, PA-C

March 16, 2019

More data are needed regarding the efficacy and safety of administering multiple lines of PARP inhibitor therapy, according to researchers.

SGO 2019

Simultaneous Sequencing of Paired Germline and Somatic Specimens Enhanced Clinical Care in Ovarian Cancer

By

Susan Moench, PhD, PA-C

March 16, 2019

Simultaneous molecular characterization of paired germline and tumor specimens may gain importance as more targeted therapies become available.

Gynecologic Cancer, SGO 2019

ARIEL3: Rucaparib Maintenance Across Age Groups in Advanced Ovarian Cancer

By

Susan Moench, PhD, PA-C

March 16, 2019

Women aged 75 and older with advanced ovarian cancer enrolled in the phase 3 ARIEL3 trial were less likely to have deleterious germline or somatic BRCA mutations.